Alnylam (NASDAQ: ALNY) R&D chief sells 4,627 shares under plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ALNYLAM PHARMACEUTICALS, INC. executive vice president and Chief R&D officer Pushkal Garg reported both an equity award vesting and share sales. On February 27, 2026, 1,908 restricted stock units were converted into common shares at no cost as the final tranche of a February 27, 2023 grant vested. That same day, he sold a total of 4,627 shares of common stock in multiple open-market transactions at prices ranging from about $328.92 to $334.39 per share under a pre-established Rule 10b5-1 trading plan adopted on November 20, 2025. After these transactions, he directly held 22,129 common shares, with additional shares held indirectly in a managed account and in a trust where his spouse is co-trustee, and he disclaims beneficial ownership of the trust shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 4,627 shares ($1,533,100)
Net Sell
9 txns
Insider
Garg Pushkal
Role
EVP Chief R&D
Sold
4,627 shs ($1.53M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,908 | $0.00 | -- |
| Exercise | Common Stock | 1,908 | $0.00 | -- |
| Sale | Common Stock | 127 | $328.92 | $42K |
| Sale | Common Stock | 2,259 | $330.73 | $747K |
| Sale | Common Stock | 1,159 | $331.49 | $384K |
| Sale | Common Stock | 942 | $332.48 | $313K |
| Sale | Common Stock | 140 | $334.39 | $47K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 26,756 shares (Direct);
Common Stock — 431 shares (Indirect, by Managed Account)
Footnotes (1)
- This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.90 to $329.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.08 to $331.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.09 to $332.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.11 to $333.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.
FAQ
What insider transactions did Pushkal Garg report for ALNY on February 27, 2026?
Pushkal Garg reported an RSU vesting and open-market share sales on February 27, 2026. 1,908 restricted stock units converted to common shares, and he sold a total of 4,627 ALNY common shares in multiple transactions that day.
What restricted stock unit (RSU) activity did Alnylam’s EVP report in the Form 4?
The Form 4 shows 1,908 restricted stock units converting into common shares at no cost. This was the third and final vesting tranche from a February 27, 2023 RSU grant that vests ratably over three years.